Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem\, Cilastatin\, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available